Positive News SentimentPositive NewsNASDAQ:NVNO enVVeno Medical (NVNO) Stock Price, News & Analysis → An utter travesty (From The Freeport Society) (Ad) Free NVNO Stock Alerts $4.72 -0.07 (-1.46%) (As of 06/13/2024 ET) Add Compare Share Share Today's Range$4.71▼$4.8150-Day Range$4.62▼$5.5052-Week Range$2.61▼$6.97Volume16,228 shsAverage Volume93,494 shsMarket Capitalization$62.92 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get enVVeno Medical alerts: Email Address Ad Manward PressLike Investing in Big Tech in the Early 2000s?More than a decade after the first Bitcoin was mined, people are finally realizing something very important... Cryptocurrencies are about more than just creating digital money.Let me tell you all about them here. About enVVeno Medical Stock (NASDAQ:NVNO)enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. Read More NVNO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVNO Stock News HeadlinesMay 9, 2024 | msn.comNVNO Stock Earnings: enVVeno Medical Beats EPS for Q1 2024May 8, 2024 | finance.yahoo.comenVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 24, 2024 | finance.yahoo.comenVVeno Medical Corporation (NVNO)April 24, 2024 | finance.yahoo.comPositive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross SymposiumApril 16, 2024 | finance.yahoo.comNew Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024April 11, 2024 | uk.investing.comenVVeno Medical hires new CCO to guide transitionApril 10, 2024 | finanznachrichten.deenVVeno Medical Corporation: enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial OfficerApril 9, 2024 | finance.yahoo.comenVVeno Medical Appoints Andrew Cormack as Its Chief Commercial OfficerMarch 16, 2024 | finance.yahoo.comNVNO Apr 2024 10.000 callMarch 15, 2024 | finance.yahoo.comenVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno OpportunityMarch 6, 2024 | finance.yahoo.comPositive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual MeetingMarch 3, 2024 | finance.yahoo.comCompanies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In GrowthFebruary 29, 2024 | finanznachrichten.deenVVeno Medical Corporation: enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateFebruary 29, 2024 | benzinga.comRecap: enVVeno Medical Q4 EarningsFebruary 29, 2024 | finance.yahoo.comenVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateFebruary 20, 2024 | finance.yahoo.comTopline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024January 6, 2024 | finance.yahoo.comenVVeno Medical Corporation's (NASDAQ:NVNO) Path To ProfitabilityDecember 29, 2023 | ca.finance.yahoo.comNVNO Jan 2024 5.000 callDecember 14, 2023 | finanznachrichten.deenVVeno Medical Corporation: enVVeno Medical Posts Company Highlights and Materials from 2023 VEITH SymposiumDecember 14, 2023 | finance.yahoo.comenVVeno Medical Posts Company Highlights and Materials from 2023 VEITH SymposiumNovember 16, 2023 | finance.yahoo.comenVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the VenoValve Pivotal Trial at the 50th Annual VEITH SymposiumOctober 26, 2023 | finanznachrichten.deenVVeno Medical Corporation: enVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateOctober 26, 2023 | msn.comenVVeno Medical files to sell 14.71M shares for holdersOctober 26, 2023 | msn.comenVVeno Medical reports Q3 resultsOctober 26, 2023 | finance.yahoo.comenVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateSee More Headlines Receive NVNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for enVVeno Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/14/2024Next Earnings (Estimated)7/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NVNO CUSIPN/A CIK1661053 Webwww.hancockjaffe.com Phone(949) 261-2900Fax949-261-2992Employees19Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,520,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-62.17% Return on Assets-57.58% Debt Debt-to-Equity RatioN/A Current Ratio29.08 Quick Ratio29.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.47 per share Price / Book1.36Miscellaneous Outstanding Shares13,330,000Free Float11,064,000Market Cap$62.92 million OptionableOptionable Beta1.05 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesRobert Andrew BermanChief Executive Officer & DirectorCraig T. GlynnChief Financial Officer & TreasurerMarc H. GlickmanChief Medical Officer & Senior Vice PresidentHamed AlaviVice President-Research, Development & QualityKey CompetitorsVivani MedicalNASDAQ:VANIMicrobot MedicalNASDAQ:MBOTBeauty HealthNASDAQ:SKINInovio PharmaceuticalsNASDAQ:INOPulmonxNASDAQ:LUNGView All CompetitorsInsiders & InstitutionsKingdon Capital Management L.L.C.Bought 34,690 shares on 5/16/2024Ownership: 4.905%Quadrature Capital LtdBought 18,872 shares on 5/15/2024Ownership: 0.142%Vanguard Group Inc.Bought 237,550 shares on 5/10/2024Ownership: 4.310%Acadian Asset Management LLCBought 6,825 shares on 5/10/2024Ownership: 0.051%RIA Advisory Group LLCBought 43,666 shares on 5/3/2024Ownership: 0.328%View All Insider TransactionsView All Institutional Transactions NVNO Stock Analysis - Frequently Asked Questions How have NVNO shares performed in 2024? enVVeno Medical's stock was trading at $5.14 at the beginning of the year. Since then, NVNO shares have decreased by 8.2% and is now trading at $4.72. View the best growth stocks for 2024 here. When is enVVeno Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 29th 2024. View our NVNO earnings forecast. How were enVVeno Medical's earnings last quarter? enVVeno Medical Corporation (NASDAQ:NVNO) released its earnings results on Wednesday, May, 8th. The company reported ($0.31) earnings per share for the quarter. Who are enVVeno Medical's major shareholders? enVVeno Medical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Kingdon Capital Management L.L.C. (4.91%), Vanguard Group Inc. (4.31%), RIA Advisory Group LLC (0.33%), Janney Montgomery Scott LLC (0.26%), Fermata Advisors LLC (0.17%) and Quadrature Capital Ltd (0.14%). Insiders that own company stock include Francis Duhay, Hamed Alavi, Matthew Jenusaitis, Robert Andrew Berman, Robert Gray and Sanjay Shrivastava. View institutional ownership trends. How do I buy shares of enVVeno Medical? Shares of NVNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NVNO) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredLike Investing in Big Tech in the Early 2000s?More than a decade after the first Bitcoin was mined, people are finally realizing something very important......Manward Press | SponsoredAn utter travestyThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enVVeno Medical Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share enVVeno Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.